Skip to main content
OpenTrials
Completed

NCT Number: NCT06474871

Virtual Reality vs Traditional Cognitive Training in Patients With Severe Acquired Brain Injury

Considerable evidence exists for using Virtual Reality (VR) for rehabilitation of acquired brain injury (ABI), with a particular focus on stroke. However, to date very little evidence has been collected in patients with ABI with different aetiologies (i.e., traumatic or anoxic brain injury) and level of severity (i.e., severe, sABI). The present multicentre study aims to overcome current literature issues as heterogeneity of populations and outcomes, small sample sizes and a lack of randomized controlled trials, which can affect the level of evidence and generalizability of results, to determine the effectiveness of a non immersive VR-based rehabilitation versus traditional cognitive training (TCT).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Polo Specialistico Riabilitativo Fondazione Don Carlo Gnocchi ONLUS, Sant'Angelo dei Lombardi, Avellino, Italy

Loading trial locations.

About this study

Background Virtual Reality (VR) refers to a computer-generated digital environment that can be experienced and interacted with as if that environment were real. VR systems are typically classified as immersive, semi-immersive, or non-immersive, with immersion referring to the level of user perception with regard to being in a virtual environment (VE) rather than the real world: immersive VR systems supply VEs with a changing field of view via head-mounted displays, and in which movement is achieved via hardware such as head trackers, hand controllers, and body motion sensors; semi-immersive VR refers to systems that use projection-based systems (e.g., driving simulators and use of shutter glasses); non-immersive VR systems include basic desktop displays and videogames.

Considerable evidence exists for using VR for rehabilitation of acquired brain injury (ABI), with a particular focus on stroke. The benefits of VR for ABI rehabilitation seem to include enhanced ecological validity, the ability to maintain experimental control over assessment and treatment standardization, and the control of task complexity. Indeed, VR can provide relatively naturalistic VEs for repeated practice of functional tasks such as activities of (instrumental) daily living which may assist with generalizing targeted skills. VR can also enhance patient motivation and active participation thanks to visual and auditory feedback, which is necessary for neurorehabilitation. Furthermore, VR tools offer the possibility to adapt the exercises to the patient's capabilities and needs and monitor their performance.

However, to date very little evidence has been collected in patients with ABI with different aetiologies (i.e., traumatic or anoxic brain injury) and level of severity (i.e., sABI). Moreover, current evidence provides some support for using VR for ABI rehabilitation, but the quality of the evidence is relatively low, and many studies include non-immersive and semi-immersive systems rather than focusing on immersive VR technology. For instance, a recent study44 investigated the effects of non-immersive VR-based training to improve executive abilities in patients with moderate to severe traumatic brain injury (TBI). Executive dysfunction is among the most common facets of cognitive impairment following TBI, involving about 48% of moderate-to-severe TBI patients. Patients received either the standard cognitive training (i.e., paper and pencil) or the VR-based cognitive training. The authors found that all patients improved their global cognitive and executive function, even though those treated with VR achieved better outcomes44. Although this study showed that VR cognitive rehabilitation can be a promising tool to improve executive functions, further studies are needed to confirm the value of VR in sABI. The present multicentre study aims to overcome current literature issues as heterogeneity of populations and outcomes, small sample sizes and a lack of randomized controlled trials, which can affect the level of evidence and generalizability of results.

Methods Study type: interventional Allocation: randomized Intervention model: parallel assignment (1:1) 28 patients will be randomly assigned to receive either 30 minutes of VR or TCT sessions at the same time each day throughout the experiment. 20 VR or TCT sessions will be applied, 5 per week for 5 weeks. Both groups will receive an additional 60 minute-comprehensive daily rehabilitation programme in the 3 months of the study. This programme consists of active limb mobilization, training on different cognitive domains, occupational therapy, language and swallowing therapy based on the patient's functional condition.

Primary endpoint

-B-A score of the Trail Making Test (TMT) according to normative data adjusted for age and education (Siciliano et al., 2019).

Secondary endpoints

  • Total score on the Disability Rating Scale;
  • System usability scale (SUS) for evaluating the Usability of VR in patients and professionals;
  • modified Barthel Index (mBI) for functional disability. Exploratory endpoints T-otal score on the Italian version of the NeuroPsychiatric Inventory;
  • Quantitative EEG;
  • Blood biomarkers (BDNF, NFL, GFAP);
  • Level of Cognitive Functioning;
  • Total score on the Galveston Orientation and Amnesia Test;
  • Scores on the Broken Hearts task (overall accuracy) and/or Trails task (baseline and shifting scores) on the Italian version of the Oxford Cognitive Screening.

Adverse Events Report: emptiness/disorientation, nausea/feeling of emptiness, headache, disorientation, dizziness, tremors/nausea/blurred vision/dizziness, nausea, vertigo and sense of unreality) will also be collected weekly in both groups from enrolment through termination of study protocol.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • LCF ≥4 at study entry;
  • Age 18-75
  • Stable clinical diagnosis (i.e., stable LCF);
  • Time post-injury between 28 days and 6 months;
  • Ability to complete the pre-test A section of the Italian version of the Trail Making Test (TMT);
  • A pathological B-A score of the TMT according to normative data adjusted for age and education;
  • Signed informed consent by the patient or by the patient's primary caregiver.

Exclusion criteria

  • Severe medical conditions that might hamper participation in the rehabilitation sessions, or influence diagnosis;
  • Previous neurodegenerative or acquired neurological diseases that affect cognitive domains (e.g., dementia)

Treatment and study plan

Khymeia®-Virtual Reality rehabilitation System (VRRS EVO SYSTEM or COMPACT VRRS ENGINE)

Device

fully immersive VR software created by clinicians and experts specialized in cognitive rehabilitation. Khymeia Devices are Medical Class 1 devices according to MDR. VRRS systems consist of a central process unit, complete with a capacitive touch screen LCD monitor.

Traditional cognitive training (TCT)

Behavioral

face-to-face approach between the therapist and the patient using paper and pencil tools and other traditional materials. The training of the executive abilities is carried out by working on categorization, planning, association processes, analogical reasoning, problem solving and coping strategies to simulate problematic situations, tailored on patients' deficits

Primary outcomes

  1. Trail Making Test (B-A score)

    Time frame: 5 weeks

    The TMT is a neuropsychological test assessing executive functions. Higher scores indicate a better performance

Secondary outcomes

  1. Trail Making Test (B-A score)

    Time frame: 1 month after treatment

    The TMT is a neuropsychological test assessing executive functions. Higher scores indicate a better performance

  2. modified Barthel Index

    Time frame: 5 weeks - 1 month after treatment

    It is a measure of functional disability, with higher scores indicating higher functional independence

  3. Disability Rating Scale

    Time frame: 5 weeks - 1 month after treatment

    It is a measure of functional disability, with higher scores indicating higher disability

  4. System Usability Scale

    Time frame: 5 weeks - 1 month after treatment

    It is a measure of usability and compliance. Higher scores indicate a better performance

Other outcomes

  1. NeuroPsychiatric Inventory

    Time frame: 5 weeks - 1 month after treatment

    It is a measure of neurobehavioural and psychiatric disorders. Higher scores indicate a more severe disorder

  2. Level of Cognitive Functioning

    Time frame: 5 weeks - 1 month after treatment

    A clinical scale assessing global cognitive functioning. Higher scores indicate a higher cognitive functioning

  3. Galveston Orientation and Amnesia Test

    Time frame: 5 weeks - 1 month after treatment

    A clinical measure of post-traumatic amnesia. Higher scores indicate a more severe amnesia

  4. Oxford Cognitive Screening

    Time frame: 5 weeks - 1 month after treatment

    A screening neuropsychological test assessing different cognitive domains. Higher scores indicate a better cognitive performance

  5. Spectral metrics

    Time frame: 5 weeks - 1 month after treatment

    Measure of quantitative EEG. Higher values indicate a better functional connectivity

  6. Microstate metrics

    Time frame: 5 weeks - 1 month after treatment

    Measure of quantitative EEG. Higher values indicate a better functional connectivity

  7. Connectivity metrics

    Time frame: 5 weeks - 1 month after treatment

    Measure of quantitative EEG. Higher values indicate a better functional connectivity

  8. Brain-derived neurotrophic factor

    Time frame: 5 weeks - 1 month after treatment

    Blood biomarker. Higher value indicate higher brain plasticity

  9. Neurofilament-Light

    Time frame: 5 weeks - 1 month after treatment

    Blood biomarker. Higher value indicate higher brain plasticity

  10. Glial fibrillary acidic protein

    Time frame: 5 weeks - 1 month after treatment

    Blood biomarker. Higher value indicate higher brain plasticity

Sponsors and collaborators

Lead sponsor

Anna Estraneo

Other

Collaborators

  • Istituti Clinici Scientifici Maugeri SpA
  • Ospedale Policlinico San Martino

Registry information

Official study title

Multicentric Study on Implementation of Virtual Reality for Rehabilitation of Cognitive Functions in Patients With Severe Acquired Brain Injury: a Randomized Controlled Trial

Acronym: VR-sABI

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Jun 26, 2024
Registry last updated
Jul 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.